ASX Share rice
Wed 05 Aug 2020 - 11:29:pm (Sydney)

PYC Share Price

PYC THERAPEUTICS LIMITEDPYCPharmaceuticals, Biotechnology & Life Sciences

PYC Company Information

Name:

PYC Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

Harry Perkins Institute Nedlands WA Australia 6009

Phone:

61 8 6151 0992

Chief Strategy Officer & Director:

Dr. Rohan Hockings J.D., MBBS (Hons.), G.D.L.P

CEO & Director:

Mr. Douglas Huey

Company Sec. & CFO:

Mr. Kevin Hart B.Com., F.C.A., B.Com, FCA

Chief Scientific Officer:

Dr. Katrin Hoffmann

Chief Bus. Officer:

Mr. Kaggen Ausma

Company Overview:

PYC Therapeutics Limited provides drug discovery research and development services utilizing Phylomer peptide libraries and proprietary screening capabilities in Australia. The company's Phylomer libraries contain various peptides that represent a source of biologically active drug leads for a range of intracellular and extracellular disease targets. It develops next generation intracellular biological therapeutics, including its own preclinical Myc, STAT 5, and YB1 oncology inhibitor payloads using its proprietary cell penetrating functional penetrating Phylomers. The company has approximately 12 patent families comprising multiple granted/allowed patents in the United States and Australia, which cover methods of making the Phylomer libraries; methods of screening them and composition-of-matter claims for Phylomer libraries; and individual Phylomer peptides discovered for therapeutic and diagnostic applications. It has a research and development collaboration with Ramot. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

PYC Share Price Information

Shares Issued:

2.93B

Market Capitalisation:

$351.77M

Earnings per Share:

$-0.002

Return On Assets (TTM):

$-0.20

Return On Equity (TTM):

$-0.24

Quarterly Revenue Growth (YOY):

-0.38

Gross Profit(TTM):

$-4,591,475

Diluted Earnings Per Share (TTM):

$-0.002

PYC CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-457,289

Change To Liabilities:

$-1,334,364

Total Cashflow From Investing Activities:

$-457,289

Net Income:

$-4,079,768

Total Cash From Operating Activities:

$-5,125,413

Depreciation:

$130.56K

Change To Account Receivables:

$-15,831

Sale Purchase Of Stock:

$-503,201

Capital Expenditures:

$457.54K

PYC Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-6,983,888

Net Income:

$-4,079,768

Gross Profit:

$-4,591,475

Operating Income:

$-7,102,101

Other Operating Expenses:

$152.51K

Income Tax Expense:

$-2,904,120

Total Revenue:

$250

Total Operating Expenses:

$7.10M

Cost Of Revenue:

$4.59M

PYC Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$401.87K

Total Stockholder Equity:

$6.30M

Other Current Liabilities:

$66.45K

Total Assets:

$6.70M

Common Stock:

$61.95M

Retained Earnings:

$-56,927,492

Cash:

$6.18M

Total Current Liabilities:

$401.87K

Property - Plant & Equipment:

$482.87K

Net Tangible Assets:

$6.30M

Total Current Assets:

$6.22M

Net Receivables:

$10.83K

Short-Term Investments:

$482.87K

Accounts Payable:

$193.74K

Non Currrent Assets (Other):

$482.87K

Short-Term Investments:

$482.87

Non Current Liabilities Total:

$0

PYC Share Price History

PYC News

13 Jul, 2020
A look at the shareholders of PYC Therapeutics Limited (ASX:PYC) can tell us which group is most powerful. Insiders...
04 Mar, 2020
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
11 Oct, 2019
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...